Previous
2007 was a year in which Abbott delivered strong performance and maintained leadership positions across its businesses, reaching a number of important milestones.
Launched a new Niaspan tablet, the leading medication for boosting HDL, or good cholesterol.
Submitted Humira for global regulatory approval for psoriasis — the fifth new Humira disease indication. Launched Humira for Crohn's disease. Achieved more than $3 billion in worldwide Humira sales in 2007.
Launched the FreeStyle Lite blood glucose monitoring system, which has automated calibration, making it easier for patients to test quickly.
Submitted a new drug application to the U.S. FDA for Simcor,a fixed-dose combination of Niaspan and simvastatin that targets both good and bad cholesterol in a single pill.
Gained market share in Europe, Asia and Latin America with Xience V, our drug-eluting stent, which demonstrated superiority over the most widely used drug-eluting stent in reducing vessel renarrowing.
Introduced PediaSure NutriPals fruit bars, the only children's snack bar with one serving of fruit in every bar.
Submitted a record number of major new products for regulatory approval in 2007, including ABT-335, our next-generation fenofibrate, and controlled-release Vicodin for pain.
Achieved double-digit sales growth across pharmaceuticals, medical products and international nutritional products in 2007.
Page Top